Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology.
By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target.
At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of immunotherapies for the benefit of the patients with high unmet needs.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 27, Rue Du Faubourg Saint-Jacques, Paris,île-De-France 75014,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- innovative approach.
- HQ
- Paris, Île-de-France
Emglev Therapeutics Questions
Emglev Therapeutics's website is https://www.emglev-therapeutics.com
Emglev Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/emglev-therapeutics
Emglev Therapeutics has
2 employees.
View email and phone details for 2
employees at Emglev Therapeutics.
Emglev Therapeutics's industry is
Biotechnology Research
Emglev Therapeutics's top competitors are
Ose Immunotherapeutics,
Mnemo Therapeutics,
Ermium Therapeutics,
Smart Immune,
Nanobiotix,
Cellectis,
Valerio Therapeutics,
Abivax,
Institut Curie,
Skymab Biotherapeutics.
Emglev Therapeutics's categories are Biotechnology Research
Emglev Therapeutics's founding year is 2023
